Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05490901
Other study ID # EX_CATH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 17, 2020
Est. completion date June 30, 2029

Study information

Verified date August 2022
Source Samsung Medical Center
Contact Jeong Hoon Yang, MD
Phone 82-2-3410-3419
Email jhysmc@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To evaluate the role of exercise hemodynamic testing in the diagnostic workup for patients with dyspnea on exertion referred to the catheterization lab.


Description:

Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that has no proven effective treatment. However, in practice, it's difficult to recognize early stage of HFpEF by resting hemodynamic study and echocardiography because the patients mainly complaint of dyspnea only during exercise but not resting condition. Accordingly, exercise stress test will be helpful to provide more information on pathophysiology, diagnosis, and severity in various cardiovascular diseases such as HFpEF, valvular heart disease, and chronic thromboembolic pulmonary hypertension. Thus, the broad objective of this proposal is to characterize the dynamic changes in cardiopulmonary mechanics during stress in patients with exertional dyspnea, establishing a comprehensive multimodality diagnostic approach to the evaluation of exercise intolerance. Specifically, this study will compare established and novel parameters derived from echocardiography and CPX with simultaneous, gold standard invasive measures of cardiovascular hemodynamics at rest and with exercise stress to define the role of noninvasive testing in the diagnostic workup for patients with dyspnea on exertion referred to the catheterization lab.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date June 30, 2029
Est. primary completion date December 31, 2028
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Subject must be at least 19 years of age. - Patients with dyspnea on exertion - Written informed consent of participating subjects after being fully briefed (for prospective analysis) Exclusion Criteria: - Patients with incomplete hemodynamic data at rest or exercise - Advanced tumor disease or other diseases with a short life expectancy - Uncontrolled systemic arterial hypertension ( > 160/100 mmHg at rest) - FEV1<50% predicted - TLC<60% predicted

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Exercise hemodynamic test
Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of exercise induced pulmonary artery wedge pressure >25 mmHg Number of Participants with Diagnosis of earlier heart failure with preserved ejection fraction based on exercise PCWP during the procedure
Secondary Proportion of exercise induced pulmonary hypertension > 30 mmHg Number of Participants with Diagnosis of pulmonary hypertension based on mean pulmonary pressure at peak exercise during the procedure
Secondary Correlation between peripheral venous pressure and right atrial pressure assumed by echocardiography Correlation between peripheral venous pressure and right atrial pressure assumed by echocardiography during the procedure
Secondary Ventilatory mechanics ratio of minute ventilation to carbon dioxide production (VE/VCO2) during the procedure
Secondary Aerobic capacity peak oxygen consumption (VO2) during the procedure
Secondary coronary flow reserve invasively measured coronary flow reserve during the procedure
Secondary index of microcirculatory resistance invasively measured index of microcirculatory resistance during the procedure
Secondary Lactate level at peak exercise Serum lactate level at peak exercise during the procedure
Secondary LA stiffness LA stiffness measured by LA strain/E/e' using Transthoracic echocardiography during the procedure
Secondary change of E/e' between at rest and peak exercise The change of E/e' between at rest and peak exercise between at rest and peak exercise
Secondary Rates of rehospitalization due to heart failure Rehospitalization due to heart failure 5 years follow-up
Secondary Rates of all-cause death Follow-up death 5 years follow-up
Secondary The change of right ventricular systolic pressure (RVSP) between at rest and peak exercise The change of RVSP between at rest and peak exercise between at rest and peak exercise
Secondary change of Tricuspid annular plane systolic excursion (TAPSE) between at rest and peak exercise The change of TAPSE between at rest and peak exercise between at rest and peak exercise
Secondary change of S' between at rest and peak exercise The change of S' between at rest and peak exercise between at rest and peak exercise
See also
  Status Clinical Trial Phase
Suspended NCT05839730 - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting NCT06379152 - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting NCT05676684 - Dapagliflozin, Spironolactone or Both for HFpEF Phase 2/Phase 3
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting NCT05715697 - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT04745013 - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart N/A
Completed NCT05126836 - Cilostazol for HFpEF Phase 2
Completed NCT05586828 - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Completed NCT06228807 - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting NCT05284617 - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF Phase 2
Recruiting NCT05562063 - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Phase 4
Recruiting NCT06027307 - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Phase 3
Withdrawn NCT05322616 - Single-Ascending Dose Study of JK07 in Subjects With HFpEF Phase 1